Wall Street brokerages expect FibroGen Inc (NASDAQ:FGEN) to announce $51.58 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for FibroGen’s earnings, with the highest sales estimate coming in at $119.30 million and the lowest estimate coming in at $18.60 million. FibroGen posted sales of $43.95 million in the same quarter last year, which suggests a positive year over year growth rate of 17.4%. The firm is expected to report its next quarterly earnings report on Tuesday, August 6th.
On average, analysts expect that FibroGen will report full year sales of $235.25 million for the current financial year, with estimates ranging from $192.50 million to $292.00 million. For the next financial year, analysts expect that the business will report sales of $310.87 million, with estimates ranging from $125.40 million to $505.00 million. Zacks’ sales averages are an average based on a survey of analysts that cover FibroGen.
FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.15. The company had revenue of $23.90 million for the quarter, compared to the consensus estimate of $20.44 million. FibroGen had a negative return on equity of 17.71% and a negative net margin of 44.14%. The company’s quarterly revenue was down 25.1% compared to the same quarter last year. During the same period last year, the business posted ($0.50) EPS.
Shares of FibroGen stock traded up $0.44 during trading hours on Friday, reaching $35.57. The stock had a trading volume of 540,218 shares, compared to its average volume of 765,578. The company has a market cap of $3.06 billion, a price-to-earnings ratio of -34.53 and a beta of 1.60. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.16 and a quick ratio of 6.16. FibroGen has a 1 year low of $33.51 and a 1 year high of $68.55.
In other FibroGen news, Director James A. Schoeneck sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $54.74, for a total transaction of $109,480.00. Following the completion of the sale, the director now owns 29,700 shares in the company, valued at approximately $1,625,778. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Pat Cotroneo sold 14,787 shares of the firm’s stock in a transaction that occurred on Thursday, February 28th. The shares were sold at an average price of $60.08, for a total value of $888,402.96. Following the sale, the senior vice president now owns 267,891 shares of the company’s stock, valued at approximately $16,094,891.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 271,427 shares of company stock valued at $13,211,151. 8.96% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of FGEN. FMR LLC grew its position in shares of FibroGen by 2.8% in the 1st quarter. FMR LLC now owns 10,029,786 shares of the biopharmaceutical company’s stock worth $545,118,000 after acquiring an additional 269,570 shares in the last quarter. BlueMountain Capital Management LLC grew its position in shares of FibroGen by 736.1% in the 1st quarter. BlueMountain Capital Management LLC now owns 151,576 shares of the biopharmaceutical company’s stock worth $8,238,000 after acquiring an additional 133,446 shares in the last quarter. Perceptive Advisors LLC acquired a new position in shares of FibroGen in the 1st quarter worth approximately $506,000. Ladenburg Thalmann Financial Services Inc. grew its position in shares of FibroGen by 15.9% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,756 shares of the biopharmaceutical company’s stock worth $205,000 after acquiring an additional 515 shares in the last quarter. Finally, Morgan Stanley grew its position in shares of FibroGen by 48.1% in the 1st quarter. Morgan Stanley now owns 385,887 shares of the biopharmaceutical company’s stock worth $20,973,000 after acquiring an additional 125,357 shares in the last quarter. Hedge funds and other institutional investors own 67.15% of the company’s stock.
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Article: What is the downside to momentum investing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.